Biotech Values

[DewDiligence]

TEVA acquires ASPX for $101.00/sh in cash—a 42% premium to Friday’s close:

http://finance.yahoo.com/news/teva-reinforces-leadership-position-cns-110000700.html

Auspex is an innovative biopharmaceutical company specializing in applying deuterium chemistry to known molecules to create novel therapies with improved safety and efficacy profiles. Its lead investigational product, SD-809 (deutetrabenazine), which leverages Auspex’s deuterium technology platform is being developed for the potential treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, with a pharmacokinetic profile that allows for lower doses resulting in a favorable safety profile.

In 2014, Auspex reported positive results from its Phase 3 clinical trial for SD-809 in Huntington’s disease, with plans to submit a New Drug Application (NDA) for this indication by mid-2015.

The nominal value of the deal is $3.2B.

CC today at 8:30am ET.